Eleven Biotherapeutics (EBIO) Swings to Q3 Profit

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of $0.95, versus $0.50 reported last year. Revenue for the quarter came in at $28.7 million, versus $100 thousand reported last year.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deutsche Bank monitors UK auto sales as Chinese exports grow
• S&P 500 may pull back before midterms, but Citi says buy the dip